Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy

Next Previous
Search
Trial Profile

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 26 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Pharmacodynamics; Registrational
  • Acronyms LIBERTY-HCM
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 24 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 01 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
    • 25 Jan 2017 This trial was completed in Italy (end date: 2016-12-08), according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top